The story has been refreshed with the latest market price action and a revised headline. Elon Musk said Wednesday that mRNA technology could fundamentally change how diseases are treated, a shift that would make medicine more of

In light of recent wins for mRNA vaccine makers, UCSC RNA Center Co-Director Jeremy Sanford describes the versatility of the mRNA platform and how it quickens vaccine production

The success of Moderna and Merck’s intismeran autogene doesn’t guarantee smooth sailing for other mRNA vaccine developers

In a new study, scientists from Johns Hopkins Medicine report that an experimental mRNA-based platform has the potential to help deliver next-generation mRNA therapeutics, including vaccines fighting against infectious disease, cancer and autoimmune conditions, faster and more efficiently than the industry standard.

Doctors and patients are excited about the possible breakthrough, but some analysts believe there’s too much hype.

An experimental mRNA vaccine allowed people with high-risk melanoma to live longer, cancer-free, in a large, closely watched trial, the pharmaceutical companies Moderna and Merck

Moderna has now swung violently in both directions for three straight sessions on the same unchanged clinical news, and the options chain hints at why this whipsaw is far from over.

Moderna and Merck's neoantigen treatment, combining a personalized mRNA cancer vaccine with the immunotherapy drug pembrolizumab significantly reduced the risk of melanoma recurrence in a phase 3 trial.

Pharmaceutical partners Moderna and Merck announced on Wednesday that their novel mRNA-based vaccine—individually tailored to target a patient’s unique cancer mutations—was effective in a late-stage clinical trial of patients with melanoma, one of the deadliest forms of skin cancer.

The next generation of mRNA medicines – including vaccines fighting against infectious disease, cancer and autoimmune conditions – may depend on a surprisingly small change: swapping one chemical modification for another.